Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: community-acquired pneumonia

The Etiology of CAP Remains Elusive – A Call to Change Antibiotic Prescribing Patterns

Posted on August 6, 2015 by Harald — No Comments ↓

Once upon a time – not so long ago – we were taught the following: Streptococcus pneumoniae was the cause of 90% of CAP cases. That statement was later modified to mean S. pneumoniae was the underlying pathogen in 90% of bacterial cases Continue reading The Etiology of CAP Remains Elusive – A Call to Change Antibiotic Prescribing Patterns→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email

Like this:

Like Loading...
Posted in Recent Literature, The News, The Viewpoint | Tagged antibiotic blog, antibiotic stewardship, ATS/IDSA Guidelines, CAP, CAP guidelines, CAP mortality, CDC, community-acquired pneumonia, diagnosis of pneumonia, diplococcus pneumoniae, EPIC study, FDA, hospitalization for CAP, inappropriate antibiotic use, penicillin, pneumococcal pneumonia, pneumococcal vaccine, pneumonitis, role of antibiotics, role of macrolides in CAP, S. pneumoniae pneumonia | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • COMPARISON OF BAFF / APRIL INHIBITORS – 2
  • COMPARISON OF BAFF / APRIL INHIBITORS
  • TELITACICEPT IN SLE
  • The Antifungal Landscape – 2
  • The Antifungal Landscape – 1
  • About DIPHTHERIA
  • Draft FDA Guidance for COCCIDIOIDOMYCOSIS
  • HANSA, Where is the Beef?
  • OLOROFIM in a TIGHT SPOT
  • Prof Brambell’s FcRn – The Story So Far

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Achaogen Allphase Pharma Consulting aminoglycoside antibiotic blog Avycaz Bayer CABP Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2025 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d